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tion of dose distributions in lung tumours have been used to correct 
DVH’s planned in a static situation with pencil beam to a dynamic situ-
ation, considering breathing motions and a more correct dose calcula-
tion.
Results: At 17 mo. after end of study there is one local relapse alone 
and 7 cases displaying distant metastasis of which 2 are combined with 
regional failure (1 T1 and 6 T2). Grade 3 toxicity was seen in 3 patients 
with dyspnoe at 3, 6 and 9 months, not correlated with pneumonitis or 
ﬁbrosis. Spirometry data will be reported. Grade 3 toxicity with pain in 
the thorax was seen in 2 patients at 9 and 12 months not associated with 
rib fracture or tumor in proximity to the thoracic wall. 13/59 (22%) did 
not have any side effects. The most common side effect at 6 weeks was 
grade I skin reactions (19 patients with grade I and 4 with grade 2). At 
17 mo. after end of study 11 pts. had obtained CR, 30 showed PR and 8 
pats. had either local failure and/or distant metastases.
Conclusion: Using 15 x 3 Gy to stage I NSCLC results in acceptable 
early toxicity and favourable local control rate non inferior to what has 
been reported with fractionated RT.
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Background: For stereotactic lung irradiation, the dose is frequently 
prescribed to an isodose surface that encompasses the Planning Target 
Volume (PTV). This method is sensitive to incorrect modeling of the 
beam penumbra. Most dose calculation algorithms present in commer-
cially available treatment planning systems model the beam penumbra 
in water correctly. However, the beam penumbra in lung is much wider 
due to radiation and particle transport effects in low-density tissue, and 
is approximated only to a reasonable accuracy by few of the available 
calculation algorithms.
The aim of this study is to determine the effect of two dose calculation 
methods, with and without heterogeneity correction, on the prescribed 
dose to the tumor and the dose distribution in surrounding tissue. 
Methods: In our institute, stereotactic treatment plans for lung consist 
of 10 - 20 non-opposing photon beams (maximum energy 10 MV). 
Beam shapes and weights are optimized using Direct Machine Param-
eter Optimization (DMPO) available in the Pinnacle treatment planning 
system. A dose of 3 x 18 Gy is prescribed on the isodose surface that 
encompasses 95% of the PTV. Dose calculation is performed using 
the collapsed cone convolution/superposition algorithm, including all 
effects of tissue heterogeneity (heterogeneous plan). This algorithm is 
proven to be accurate in the presence of tissue heterogeneities through 
measurements in phantoms and comparison with Monte Carlo simula-
tions. To simulate an inaccurate dose calculation, we recalculated for 
15 patients the clinical treatment plan without heterogeneity corrections 
(homogeneous plan) while maintaining the number of Monitor Units 
(MU) from the clinical plan. The following dose parameters were com-
pared between the two plans: absolute isodose surface encompassing 
95% of the PTV (Dpres), relative maximum dose in the PTV (Dmax), 
ratio of the 50% prescription isodose volume to the PTV (R50), maxi-
mum dose 2 cm from PTV (D2cm), and percentage of lung volume 
receiving 20 Gy or more (V20).
Results: Compared to the heterogoneous plan, Dpres of the homoge-
neous plan increased from 54 Gy (by deﬁnition) to an average of 59 ± 
4 Gy (range 54 to 67 Gy). Due to increased attenuation and tightening 
of the beam penumbra in the homogeneous plan, Dmax was lower for 
the homogeneous plans (average 124% vs. 132%), while dose fall-off 
outside the PTV was steeper. The latter is reﬂected in a lower R50 for 
the homogeneous plans (4.2 ± 0.8) than for the heterogeneous plan (4.9 
± 1). D2cm and V20 were comparable for the two calculation methods 
(29 ± 2 Gy and 5 ± 2 %, respectively).
Conclusions: The absence of any heterogeneity correction (as required 
by some trial protocols) results in profound errors in dose distributions 
and the prescribed dose of stereotactic lung irradiation. Any dose calcu-
lation algorithm that does not predict penumbra broadening accurately 
(e.g. pencil beam algorithms), will result in errors in the calculated dose 
distributions which will affect the dose. The quality of the dose calcula-
tion algorithm is therefore an important parameter when comparing the 
local control and toxicity results of stereotactic studies in lung.
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Purpose: Assess the outcomes of non-small cell lung cancer (NSCLC) 
patients presenting with brain metastases (BM). 
Background: The brain is a common site of metastases and fre-
quently the ﬁrst site of treatment failure in non-small cell lung cancer 
(NSCLC). Patents presenting with synchronous BM may represent 
a unique population that could potentially beneﬁt from aggressive 
therapy. At this time, generally accepted treatment guidelines have not 
been established for these patients. 
Methods: Retrospective review of patients presenting with NSCLC 
with synchronous BM. Patients were assessed regarding treatment for 
both intracranial and intrathoracic disease. Aggressive treatment to 
the brain included either craniotomy or gamma knife radiosurgery and 
aggressive treatment to the primary lung cancer consisted of surgery, 
chemoradiation therapy or both.
Results: 75 NSCLC patients presented with synchronous BM treated 
between 1998-2002. 34 M: 41F, median age 60 years (40 -85), and 
median Karnofsky score 79 (40 - 100). Sixty-percent (45 pts) had 
extracranial metastases at the time of diagnosis, and 36 patients (48%) 
had a single brain metastasis. Treatment was considered aggressive 
(e.g. craniotomy or Gamma Knife radiosurgery) for CNS disease 43 
patients and for chest disease (e.g. surgery or chemoradiotherapy) in 
20 patients. With a median follow-up was 15 months (1-107), me-
dian survival was 8.4 months in the aggressive treatment group and 
7.7months in the “palliative” treatment group (p= 0.44). Ten patients 
survived more than 2 years (median 48 months for this cohort), and 
9/10 received aggressive CNS treatment while 5/10 recieved aggressive 
intrathoracic treatment. The patterns of relapse were similar in the ag-
gressive and palliative treatment groups. Twenty one patients recurred 
in the brain, (10/43 in aggressive treatment group, 11/36 palliative 
group). 9 patients recurred or demonstrated progressive disease in the 
lung (1/12 aggressive treatment group, 8/63 in non-aggressive group). 
In an analysis of prognostic factors including performance status, 
